Sana Biotechnology, Inc.
SANA
$3.20
-$0.06-1.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -0.19% | -29.47% | -26.81% | -37.11% | -29.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.35% | 1.46% | -26.04% | -16.45% | -53.71% |
| Operating Income | 22.35% | -1.46% | 26.04% | 16.45% | 53.71% |
| Income Before Tax | 4.41% | -19.88% | 29.66% | -86.51% | 54.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 4.41% | -19.88% | 29.66% | -86.51% | 54.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.41% | -19.88% | 29.66% | -86.51% | 54.05% |
| EBIT | 22.35% | -1.46% | 26.04% | 16.45% | 53.71% |
| EBITDA | 21.36% | -3.14% | 26.37% | 15.64% | 55.59% |
| EPS Basic | 17.99% | -2.65% | 36.42% | -83.40% | 57.97% |
| Normalized Basic EPS | 34.16% | 9.88% | 33.19% | 21.45% | 57.43% |
| EPS Diluted | 17.99% | -2.65% | 36.42% | -83.40% | 57.97% |
| Normalized Diluted EPS | 34.16% | 9.88% | 33.19% | 21.45% | 57.43% |
| Average Basic Shares Outstanding | 16.53% | 16.75% | 10.65% | 1.69% | 9.34% |
| Average Diluted Shares Outstanding | 16.53% | 16.75% | 10.65% | 1.69% | 9.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |